Project Grant R01CA301640
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $590K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
- The National Cancer Institute awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. $119,597 on July 3, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical training and research in cancer immunotherapy. The project, "Engineering Antigen-Specific Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy of Head and Neck Squamous Cell Carcinoma," will systematically investigate antigen-reactive tumor-infiltrating lymphocytes (TIL)...
- The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), has awarded a $328,575 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. This 3-year grant, with a start date of September 1, 2024, will support research aimed at "Reversing Exhaustion of Tumor-Infiltrating Lymphocytes for Improvement of Adoptive Cell Therapy." As a National Cancer Institute-designated comprehensive cancer...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,837,644 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding will support "Translational Studies for Targeted Alpha-Particle Therapy for Rare Melanomas" over a 4-year period from September 1, 2023 to August 31, 2027. This project grant aims to advance research into innovative cancer therapies, specifically exploring...
- The National Cancer Institute awarded Mayo Clinic $667,710 on March 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a randomized Phase 2 trial evaluating blood-based tumor and immune markers for risk stratification and treatment response monitoring in oligometastatic castration-sensitive prostate cancer. The project integrates prostate cancer-derived extracellular vesicles and circulating tumor DNA as blood markers to identify patients who will benefit from...
- This Project Grant award, totaling $328,574.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding supports a 3-year research project to quantify the spatial properties of immunosuppressive macrophages in papillary renal cell carcinoma. The research aims to advance the understanding of cancer biology and immunotherapy, with...
- The National Cancer Institute awarded a cooperative agreement totaling $225,511 to H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. on March 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a plasma-based multimodal digital PCR assay for detecting androgen receptor somatic alterations in metastatic castration-resistant prostate cancer. The assay will quantify AR amplifications, mutations, and splicing variants as a...
- The National Cancer Institute awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. $682,495 under the Cancer Biology Research program (CFDA 93.396) on June 1, 2026. The research characterizes the SPOP-BRAF-mTORC1 signaling axis in melanoma pathogenesis, with focus on understanding BRAF regulation through proteolytic and non-proteolytic polyubiquitination, lysine-acetylation, and AURKA-mediated phosphorylation. The project investigates mechanisms by which SPOP inactivation...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Mississippi Medical Center $156,000 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize gamma-delta T cell receptor-mediated signaling for improved cancer immunotherapy. The project focuses on investigating how gamma-delta T cells can be engineered to enhance cancer immunotherapy effectiveness. Gamma-delta T cells...
- The U.S. Department of Defense's Defense Health Agency awarded a $481,749 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) under the Military Medical Research and Development program (CFDA 12.420). The grant, effective September 30, 2023 through September 29, 2026, will support research to dissect the spatial molecular architecture of the transformed cutaneous T cell lymphoma tumor microenvironment, with the goal of identifying novel...
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $798,673 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on July 15, 2025, with an ultimate completion date of June 14, 2029. The award funds research to characterize the role of aberrant FGD1 splicing in brain and bone metastasis in clear cell renal cell carcinoma. This research aims to advance understanding of metastatic mechanisms...